Glutathione
← Back to LibraryCompound Profile
Glutathione is reviewed here for skin, hair, and tissue-quality context.
Research Summary
Safety notices, literature searches, limited protocol data
Skin, Hair, Tissue quality
Target context: Antioxidant
Limited, unclear, or affected by safety flags.
Claims need extra caution because evidence is thin or safety flags apply.
Route(s)
Subcutaneous, Intramuscular
Typical dose
100mg
Dosing window
Anytime
Receptor / target
Antioxidant
Properties
Not listed
Pre-mixed
No
How Glutathione works in the body
Glutathione is an antioxidant popular for skin brightening.
Skin (Mixed / FDA caution)
Used for skin brightening, but human evidence for skin-lightening is limited and IV use carries safety flags.
Educational only, not medical advice. Labels describe the type of research behind each area, not a recommendation.
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 100mg 1x daily | Standard / Gradual Approach (2 mL = 300 mg/mL). Six days per week. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100 mg | Initiation. |
| Weeks 3-4 | 150 mg | Escalation. |
| Weeks 5-8 | 200 mg | Peak dose phase. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied mainly in dermatology, wound healing, pigmentation, extracellular matrix, hair/skin biology, or cosmetic-formulation research. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Antioxidant. Route(s): Subcutaneous, Intramuscular. Dosing window on page: Anytime. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Aesthetic peptides often have dermatology or cosmetic-formulation evidence that may not translate to injectable or systemic use.
- Skin cancer surveillance, pigmentation, allergy, sterility, scarring, and mineral exposure are important source-linked safety themes.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-4, 100mg 1x daily; Alternative Titration: Weeks 1-2, 100 mg.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor skin lesion changes, pigmentation, copper/mineral exposure, allergy, scarring, infection, and route-specific irritation.
Selected medical sources
Independent evidence
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Asthma (inhaled form only): the contraindication is route-specific; nebulized/inhaled glutathione has been associated with bronchospasm in asthmatic subjects; the subcutaneous and intramuscular injectable routes used in this database do not carry this bronchospasm risk.
- Concurrent chemotherapy agents that rely on oxidative mechanism for cancer cell killing (alkylating agents, platinum compounds: cisplatin, carboplatin, oxaliplatin): glutathione is a primary detoxification mechanism for these drugs; elevated intracellular GSH in cancer cells is a known mechanism of chemotherapy resistance; exogenous glutathione during platinum-based or alkylating chemotherapy could reduce chemotherapy efficacy through enhanced cancer cell GSH-mediated drug detoxification.
- Concurrent nitroglycerin therapy: glutathione is required for the bioactivation of organic nitrates; paradoxically, GSH depletion is the mechanism of nitrate tolerance, and high-dose exogenous glutathione could restore nitrate sensitivity abruptly in subjects who have developed tolerance.
- Known hypersensitivity to glutathione, its tripeptide components (γ-glutamic acid, cysteine, glycine), or formulation excipients.
- Severe renal impairment: the kidneys play a role in glutathione metabolism and cysteine recycling; in severe renal failure the pharmacokinetics of exogenous GSH are altered.
- Wilson's disease (copper overload disorder): glutathione participates in copper metabolism through its cysteine thiol group; in Wilson's disease where copper accumulation is the pathological problem, alterations in glutathione-mediated copper handling require medical supervision.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Injection site pain: the most consistently reported adverse effect; glutathione at concentrations of 200-300mg/mL is slightly acidic and can produce notable injection site burning and soreness compared to standard peptide injections; most pronounced with IM administration; managed by slower injection rate and warming the solution to body temperature.
- Skin lightening and loss of melanin: the intended cosmetic effect becomes an adverse effect in subjects who did not desire pigmentation reduction or who experience uneven lightening; the effect is dose-dependent, progressive over weeks, and reversible upon discontinuation but gradual in reversal.
- Uneven skin lightening: hypopigmentation may be patchy rather than uniform, particularly at injection sites (local concentration effect) versus systemic distribution; typically equilibrates with continued use as systemic distribution homogenizes.
- Zinc depletion: sustained high-dose glutathione supplementation has been associated with reduced serum zinc; zinc supplementation concurrent with long-term glutathione cycles is advisable.
- Mild gastrointestinal discomfort (uncommon at injectable doses): not a primary concern with subcutaneous/IM routes versus oral.
- Temporary worsening of melanoma surveillance: glutathione's tyrosinase inhibition and melanin reduction effects could theoretically alter the appearance of melanocytic lesions in a manner that affects dermatological surveillance; all existing moles should be documented before initiating glutathione cycles.
- Paradoxical pro-oxidant effect at very high doses: at supraphysiological concentrations, the GSH/GSSG redox couple can shift in a pro-oxidant direction; this is a theoretical concern at doses far exceeding the standard protocol and not clinically observed at the 100-200mg doses used in these protocols.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.